The GenCRISPR™ Ultra eSpCas9 product line provides customers with a selection of research use, basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges.
GenCRISPR™ Ultra eSpCas9-N-NLS Research, tag-free is a mutant form of Cas9 nuclease and is produced by expression in an E. coli strain carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization signal (N-NLS). GenCRISPR™ Ultra eSpCas9-N-NLS Research, tag-free delivers higher fidelity and less off-target activity than wild-type SpCas9 nuclease.
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.